Pfizer Inc. (PFE) Announced Q1 2026 Earnings on May 5, 2026, Reporting "revenues were $14.5 billion".

Pfizer Inc. reported first quarter 2026 "revenues were $14.5 billion", which represented an operational increase of 2 percent.

For the first quarter, "reported diluted earnings per share was $0.47 and adjusted diluted earnings per share was $0.75". The company stated its "adjusted gross margin for the first quarter was approximately 76%" and its first quarter 2026 "adjusted operating margin was strong at 38%". Management also noted that "total adjusted operating expenses were $5.5 billion for the first quarter".Executives highlighted strategic progress, noting "2 significant legal developments that improved our growth profile post 2028". These included "settlement agreements resolving infringement of patent related to VYNDAMAX" and a "Belgium court ruling regarding COMIRNATY contracts with EU member countries". Management noted that "embedding the use of artificial intelligence across our company is a key strategic priority" to "compress time lines and improve vision making". Additionally, the company expects "$700 million in savings from our Phase I of our manufacturing optimization program this year".Pfizer reaffirmed its full year 2026 guidance, expecting "total company revenues in the range of $59.5 billion to $62.5 billion and adjusted diluted earnings per share in the range of $2.80 to $3 a share". The company stated its "launched and acquired products had a tremendous start to the year with 22% growth". Key product updates included "notable EV-304 study findings for PADCEV" in bladder cancer, "positive top line results" from the "Phase III MagnetisMM-5 study of ELREXFIO" in multiple myeloma, and plans to "advance 10 Phase III studies this year" in obesity therapies following the Metsera acquisition.